Press Materials
Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.
Celon Pharma on track to conquer the global antidepressant market worth between USD 2.5 and 4 billion.
Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor
Celon Pharma S.A. initiates clinical development of its own cutting edge anti-cancer drug – an FGFR inhibitor
Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial
20180105_Completed administration of the Esketamine-based drug to all subjects of the first part of the phase 1 trial
Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex on Scandinavian markets
20171130_Celon Pharma has positively concluded the decentralised procedure (DCP) for Salmex on Scandinavian markets
Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression
20171128_Celon Pharma S.A. begins a clinical programme for Esketamine in the treatment of drug-resistant depression
Stable business foundation with a good prospect for presence in new European markets.
20171115_ Stable business foundation with a good prospect for presence in new European markets.
Steady income and positive sales dynamics of Celon Pharma S.A. in the first half of 2017
20170920_Steady income and positive sales dynamics of Celon Pharma S.A.
Celon Pharma S.A. submitted an application for a permit to build a Research and Development Centre in Kazuń Nowy.
20170727_Celon Pharma S.A. submitted an application for a permit to build a Research and Development Centre in Kazuń Nowy.
Celon Pharma S.A. received a positive assessment and funding recommendation from the National Centre for Research and Development (NCBiR) for 3 projects of developing innovative medicinal products
20170710_Celon Pharma S.A. received a positive assessment and funding recommendation from the National Centre for Research and Development (NCBiR) for 3 projects of developing in